(Q37885723)

24 August 2017

1 reference

title

Gastrointestinal effects of aspirin (English)

1 reference

24 August 2017

1 reference

2

Angel Lanas

1 reference

24 August 2017

Carlos Sostres

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

7 June 2011

1 reference

Nature Reviews Gastroenterology & Hepatology

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

385-394

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2011.97

24 August 2017

exact match

0 references

cites work

Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Mechanisms for rapid re-epithelialization of the gastric mucosal surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Pharmacodynamic of cyclooxygenase inhibitors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phospshodiesterase in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Aspirin dose for the prevention of cardiovascular disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

The effect of arachidonic acid and its metabolites on acid production in isolated human parietal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Endoscopy in asymptomatic minidose aspirin consumers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

How to advise aspirin use in patients who need NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Aspirin to prevent heart attack and stroke: what's the right dose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Nonsteroidal antiinflammatory drugs and the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Glucose and citrate reduce the permeability changes caused by indomethacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Upper gastrointestinal bleeding associated with antiplatelet drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Proton pump inhibitor and clopidogrel interaction: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

First Spanish consensus on peptic ulcer bleeding management. Consenso sobre Hemorragia Digestiva por Úlcera Péptica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Role of prostaglandins, nitric oxide, sensory nerves and gastrin in acceleration of ulcer healing by melatonin and its precursor, L-tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Optimal management of peptic ulcer disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Aspirin dose and duration of use and risk of colorectal cancer in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Antithrombotic drugs: insights from cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Nitric oxide in mucosal defense: a little goes a long way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Modulation of thiol homeostasis induced by H2S-releasing aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Inflammatory mediators in gastrointestinal defense and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Markedly reduced intestinal toxicity of a diclofenac derivative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with potential difference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Effect of 16,16-dimethyl prostaglandin E2 on the surface hydrophobicity of aspirin-treated canine gastric mucosa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Mechanism of aspirin injury to human gastroduodenal mucosa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Review article: gastroduodenal bicarbonate secretion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Protection of the gastroduodenal mucosa by prostaglandins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Possible involvement of non-steroidal anti-inflammatory drugs in vagal-mediated gastric acid secretion in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Gastric changes in coronary-operated patients with low-dose aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

In vitro recovery of canine gastric mucosal surface hydrophobicity and potential difference after aspirin damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.97

Profile of gastric potential difference in man. Effects of aspirin, alcohol, bile, and endogenous acid

31 March 2020

1 reference

12 December 2020

Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration

1 reference

12 December 2020

Inflammatory mediators in gastrointestinal defense and injury

1 reference

12 December 2020

Determinants of the short-term gastric damage caused by NSAIDs in man.

1 reference

12 December 2020

Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group

1 reference

12 December 2020

Risk assessment and aspirin use in Asian and Western populations

1 reference

12 December 2020

Acetylsalicylic acid consumption in patients with diabetes mellitus

1 reference

12 December 2020

Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group

1 reference

12 December 2020

Effect of aspirin and related compounds on the fine structure of mouse gastric mucosa

1 reference

12 December 2020

Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase

1 reference

12 December 2020

Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study

1 reference

12 December 2020

Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2011.97

1 reference

24 August 2017

1 reference